{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007259","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.292738+00:00","generated_at":"2026-05-22T00:33:44.908640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ArriVent Q1 cash $205.5M, net loss $64.4M; Phase 3 enrollment completed for firmonertinib","bullets":["Cash $205.5M as of March 31, 2025; net loss $64.4M (vs $17.4M YoY) due to $40M upfront payment to Lepu for ARR-217.","Completed enrollment in global pivotal Phase 3 FURVENT study for firmonertinib in first-line NSCLC EGFR exon20 insertion mutations.","Plans to provide update on firmonertinib in EGFR PACC mutant NSCLC in Q2 2025; topline Phase 3 data expected in 2025.","First IND for ARR-217 (CDH17 ADC) submitted in China; initial focus on colorectal, pancreatic, and other GI cancers.","Appointed Merdad Parsey, former Gilead CMO, to Board of Directors in April 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007259","json":"https://secwatch.observer/filing/0001558370-25-007259.json","markdown":"https://secwatch.observer/filing/0001558370-25-007259.md","text":"https://secwatch.observer/filing/0001558370-25-007259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/0001558370-25-007259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/avbp-20250512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:33:44.908640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}